Go to:
Logótipo
You are here: Start > Publications > View > Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?
Today is sunday
Inauguração da Exposição A Velha Escola Morreu
Publication

Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?

Title
Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?
Type
Another Publication in an International Scientific Journal
Year
2020
Authors
Almeida, CF
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Oliveira, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Ramos, MJ
(Author)
FCUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Teixeira, N
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Amaral, C
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Journal
Vol. 177
ISSN: 0006-2952
Publisher: Elsevier
Other information
Authenticus ID: P-00S-1J4
Abstract (EN): Endocrine therapy is currently the main therapeutic approach for estrogen receptor-positive (ER+) breast cancer, the most frequent subtype of breast cancer in women worldwide. For this subtype of tumors, the current clinical treatment includes aromatase inhibitors (AIs) and anti-estrogenic compounds, such as Tamoxifen and Fulvestrant, being AIs the first-line treatment option for post-menopausal women. Moreover, the recent guidelines also suggest the use of these compounds by pre-menopausal women after suppressing ovaries function. However, besides its therapeutic efficacy, the prolonged use of this type of therapies may lead to the development of several adverse effects, as well as, endocrine resistance, limiting the effectiveness of such treatments. In order to surpass this issues and clinical concerns, during the last years, several studies have been suggesting alternative therapeutic approaches, considering the function of aromatase, ER alpha and ER beta. Here, we review the structural and functional features of these three targets and their importance in ER+ breast cancer treatment, as well as, the current treatment strategies used in clinic, emphasizing the importance of the development of multi-target compounds able to simultaneously modulate these key targets, as a novel and promising therapeutic strategy for this type of cancer.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 14
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Discovery of a multi-target compound for estrogen receptor-positive (ER+) breast cancer: Involvement of aromatase and ERs (2021)
Article in International Scientific Journal
Almeida, CF; Teixeira, N; Oliveira, A; Augusto, TV; Correia da Silva, G; Ramos, MJ; Pedro A Fernandes; Amaral, C

Of the same journal

Gold nanostructures as mediators of hyperthermia therapies in breast cancer (2021)
Another Publication in an International Scientific Journal
Granja, A; Pinheiro, M; Sousa, CT; Salette Reis
Adenosinergic signalling in chondrogenesis and cartilage homeostasis: Friend or foe? (2020)
Another Publication in an International Scientific Journal
Pinto Cardoso, R; Pereira Costa, F; Pedro Faria, J; Bandarrinha, P; Bessa Andrês, C; Correia de Sá, P; Bernardo Noronha Matos, J
4′-Methoxy-2-styrylchromone a novel microtubule-stabilizing antimitotic agent (2008)
Article in International Scientific Journal
Joana Marinho; Madalena Pedro; Diana C.G.A. Pinto; Artur M.S. Silva; José A.S. Cavaleiro; Claudio E. Sunkel; Maria São José Nascimento
4 '-Methoxy-2-styrylchromone a novel microtubule-stabilizing antimitotic agent (2008)
Article in International Scientific Journal
Joana Marinho; Madalena Pedro; Diana C G A Pinto; Artur M S Silva; Jose A S Cavaleiro; Claudio E Sunkel; Maria Sao Jose Nascimento

See all (20)

Recommend this page Top
Copyright 1996-2024 © Faculdade de Engenharia da Universidade do Porto  I Terms and Conditions  I Accessibility  I Index A-Z  I Guest Book
Page generated on: 2024-11-03 at 06:00:00 | Acceptable Use Policy | Data Protection Policy | Complaint Portal